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Gregory L. Moneta, MD, Section EditorCombination Antiplatelet Therapy for Secondary Stroke Prevention:
Enhanced Efficacy or Double Trouble?
Usman MHU, Notaro LA, Nagarakanti R, et al. Am J Cardiol 2009;103:
1107-12.
Conclusion: Aspirin and clopidogrel combined are associated with more
bleeding than aspirin or clopidogrel alone.
Summary: Aspirin is effective as an antithrombotic agent for secondary
stroke prevention. It reduces the risk of secondary stroke 15% to 20% compared
with placebo (BMJ 1994;308:81-106) but fails to prevent many events; there-
fore, other antithrombotic agents have been investigated for secondary stroke
prevention. All antithrombotic agents, however, carry a bleeding risk, and some
bleeding episodes are fatal; for example, bleeding associated with antithrom-
botic agents for secondary prevention leads to higher mortality in patients with
acute coronary syndromes (Circulation 2006;114:774-82). In this report the
authors sought to compare bleeding risk associated with secondary stroke
prevention regimens for noncardioembolic strokes. They focused on analyzing
recent studies of combinations of antiplatelet agents.
The authors assessed annualized rates of total and major bleeding
events in secondary stroke prevention trials of antithrombotic agents. They
searched Medline for major randomized clinical studies with a follow-up
duration of1 year and identified 13 studies. They used pooled data sets to
compare mean bleeding rates for aspirin (325 mg/d), clopidogrel, anti-
coagulants (warfarin and other vitamin K antagonists), aspirin plus clopi-
dogrel, and aspirin plus extended-release dipyridamole (ER-DP). Total
bleeding occurred at mean rates of 4.8% with aspirin (325 mg/d) alone,
2.9% with clopidogrel alone, 3.6% with aspirin plus ER-DP, 10.1% with
aspirin plus clopidogrel, and 16.8% with anticoagulation. Mean bleeding
occurred at mean rates of 1% with aspirin (325 mg/d) alone, 0.85% with
clopidogrel, 0.93% with aspirin plus ER-DP, 1.7% with aspirin plus clopi-
dogrel, and 2.5% with anticoagulation.
Comment: The 13 studies analyzed in this article included 87,205
patients. The estimated bleeding risks associated with various forms of
pharmacologic secondary stroke prophylaxis are therefore probably accu-
rate. However, reporting of bleeding rates is hampered by lack of a common
classification scheme for bleeding episodes. The main point of this article is
to point out that bleeding rates with combinations of antiplatelet therapies
or anticoagulation, in patients with previous stroke, are really quite signifi-
cant. In all but 1 of the 13 studies analyzed, the mean patient age was 70
years. If one wishes to extrapolate these data to vascular surgical patients,
who are in many cases older than those analyzed here, the likely risk of dual
antiplatelet therapy might be even higher.
Vascular Medicine
Metabolic Syndrome, Inflammation, and Risk of Symptomatic Periph-
eral Artery Disease in Women: A Prospective Study
Conen D, Rexrode KM, Creager MA, et al. Circulation 2009;120:1041-7.
Conclusion: Metabolic syndrome can predict future symptomatic
peripheral arterial disease (PAD) in women, with the risk largely mediated by
inflammation and endothelial activation.
Summary: Metabolic syndrome is a cluster of cardiovascular risk
factors associated with insulin resistance and obesity. Its association with a
moderate increase in coronary artery disease, stroke, and cardiovascular
mortality is well established. The association between metabolic syndrome
and PAD is less clear. One prospective study indicated an increased risk of
PAD associated with metabolic syndrome; however, much of the risk related
to the effect to diabetes alone (Diabetes Care 2007;30:13009-3104). A
second study did not find a significant association between metabolic
syndrome and incident PAD (Atherosclerosis 2009;203:604-9).
High-sensitivity C-reactive protein (hsCRP) is now established as a
predictor of cardiovascular morbidity and mortality and as a marker of
inflammation associated with atherosclerosis. In this study the authors
sought to assess the relationship between metabolic syndrome and inflam-
mation with future symptomatic PAD in a large group of essentially healthy
women. This was a prospective cohort study of 27,111 women free of
baseline cardiovascular disease who were participating in the Women’s
Health Study. During a median cohort follow-up of 13.3 years, participants
were monitored for development of incident symptomatic PAD as defined
by development of intermittent claudication or need for lower extremity
arterial revascularization. Of these, 114 women progressed to this end point.
Cox proportional hazard models were used to compare PAD risk in women
with and without metabolic syndrome. Also investigated were relationships
between metabolic syndrome and inflammation as measured by hsCRP and
soluble intercellular adhesion molecule-1 (ICAM-1).
782In women with metabolic syndrome, there was a 62% increase risk of
future PAD (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.10-
2.38). With risk adjustments, there was an additional 21% risk increase per
additional metabolic syndrome-defining trait (adjusted HR, 1.21; 95% CI,
1.06-1.39). In women with and without metabolic syndrome, median levels
were, respectively, 4.0 vs 1.5 mg/L for hsCRP (P .001) and 1374 vs 333
ng/mL for soluble ICAM-1 (P  .0001). Adding hsCRP and soluble
ICAM-1 to the multivariable model resulted in risk associated with meta-
bolic syndrome being substantially attenuated and no longer significant
(HR, 1.14; 95% CI, 0.75-1.73).
Comment: The study suggests a mechanistic link between metabolic
syndrome and inflammation with the development of PAD in women.
Conclusions are limited by the facts that most of the women were Caucasian
and only symptoms or the need for operation were used to define the
presence of PAD. Clearly, many asymptomatic patients with PAD could have
been missed. Nevertheless, symptomatic PAD is certainly an important
clinical end point, and the study does suggest mechanistic links between risk
factor clustering and onset of PAD in woman.
Outcome Following Endovascular vs. Open Repair of Abdominal
Aortic Aneurysm: A Randomized Trial
Lederle FA, Freischlag JA, Kyriakides TC, and the Open vs. Endovascular
Repair (OVER) Veterans Affairs Cooperative Study Group. JAMA 2009;
302:1535-42.
Conclusion: Perioperative mortality is lower for endovascular than
open AAA repair. There is no significant difference in all cause-mortality at 2
years.
Summary: Previous randomized trials of open vs endovascular aneu-
rysm repair have shown reduced perioperative mortality, hospital stay, and
intensive care unit days in the endovascularly treated patients. In random-
ized trials conducted in Europe, at 2 years the early survival advantage of the
endovascular patients was lost, while the relative effects of endovascular and
open repair on quality of life and erectile function remain unclear. This study
was conducted in 881 veterans aged 49 years drawn from 42 Department
of Veterans Affairs Medical Centers. To be eligible for the trial, the patient
had to have had an abdominal aortic aneurysm (AAA) 5 cm or an AAA
4.5 cm with rapid enlargement or secular morphology. Iliac dilatation was
restricted to3 cm. The current report is a planned interim report of 2-year
outcomes of an ongoing 9-year trial. This report describes the period from
October 15, 2002, to October 15, 2008. There were 444 patients random-
ized to elective endovascular repair and 437 to open repair. The primary
outcome measures included procedure failure, secondary therapeutic proce-
dures, length of stay, erectile dysfunction, mortality, major morbidity, and
quality of life as assessed by the Short Form 36Health Survey and EuroQOL
questionnaires.
There were no significant differences between the demographics of the
two patient groups with the exception of greater prevalence of aspirin use in
the open vs endovascular cohort. Mean follow-up was 1.8 years. Before 2
years, 80% of patients (n  710) had completed follow-up or had died.
Perioperative mortality was higher in the open vs endovascular patients,
although mortality was low in both groups (0.2% vs 2.3%; P .006). At 30
days or during hospitalization, mortality was 0.5% in the endovascular group
vs 3% in the open group (P .004). Mortality did not vary with diameter of
the AAA.
At 2 years, there was no significant difference in all-cause mortality in
the endovascular vs open groups (7% vs 9.8%; hazard ratio, 0.7; 95%
confidence interval, 0.4-1.1; P  .13). After the perioperative period,
mortality was similar in the two groups (6.1% vs 6.6%). There were four late
aneurysm-related deaths in the endovascular group and no late aneurysm-
related deaths in the open group. There were no significant differences in
mortality in any prespecified subgroups for analysis, including coronary
artery disease (P .06). A trend was noted for increasedmortality in patients
treated with AneurRx grafts vs those treated with Zenith or Excluder grafts,
but this did not reach statistical significance. The groups did not differ
significantly in health-related quality of life or erectile function during the 2
years of follow-up. There were no differences in observed secondary proce-
dures in the two groups, with 61 secondary therapeutic procedures in the
endovascular group, of which 42 were catheter-based procedures. There
were 55 secondary procedures in the open group that included 24 incisional
hernia repairs.
Comment: Virtually all the Department of Veterans Affairs hospitals
that participated in this study were university affiliated. Therefore, the
exemplary mortality rates with both open and endovascular repairs may not
be generalized to the United States population. Nevertheless, it is clear it is
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There is not a lot that is surprising here. Operative mortality was lower
with endovascular repair and long-termmortality was no different, reflecting
previous studies. However, secondary intervention rates were similar in the
open vs endovascular repair groups. This difference from previous studies
likely reflects a more conservative approach to treatment of type II endoleaks
as well as the inclusion of non-graft-related procedures (ie, incisional hernia
repairs) in the open cohort. Erectile dysfunction and quality of life were
similar in the two groups at 2 years, likely reflecting similar underlying levels
of comorbidity. An important factor not addressed in this study is relative
overall cost of the two procedures.
Projected Cancer Risks from Computed Tomographic Scans Per-
formed in the United States in 2007
Berrington de Gonzalez A, Mahesh M, Kim K-P, et al. Arch Intern Med
2009;169:2071-7.
Conclusion: Use of computed tomography (CT) scans contributes
significantly to future total cancer risk.
Summary: Ideally, determining cancer risk fromCT scans would entail
a large-scale study with life-long follow-up. This is impractical, and alterna-
tively, risk assessment can be obtained using risk projection models. In the
early 1990s, the authors used such models and estimated 0.2% of incident
cancers in the United Kingdom were attributable to CT scans (Lancet
2004;363:345-55). CT use in the United States is now 10 times higher than
in the early 1990s, and thus, incident cancers related to CT scanning maybe
as high as 1.5% to 2% (N Engl J Med 2007;357:2277-84). Estimates of the
current frequency of CT scan use by CT scan type (Health Phys 2008;95:
502-7) combined with radiation risk models based on the National Research
Council’s “Biologic Effects of Ionizing Radiation” report (BEIR VIII—
Phase 2, National Academics Press, Washington, DC, 2005), was used in
this study to estimate future cancer risks from CT scans performed in 2007.
The goal was to provide an evaluation of the public health effect of CT-
induced cancers and to determine which age groups and scan types were
associated with the highest risk. Monte Carlo Simulation was used to
estimate the median number of radiation-related incident cancers with 95%
uncertainty limits (UL).
The authors estimated approximately 29,000 (95% UL, 15,000-
45,000) future cancers will be related to CT scans performed in 2007 in the
United States. Scans of the abdomen and pelvis, chest, and head, and chest
CT angiography, will be the largest contributors to new cancers (n 
14,000, 95% UL 6900-25,000 for abdomen and pelvis; n  41,000, 95%
UL 1900-8100 from chest scans; n  4000, 95% UL 1100-8700 for head
scans; and n  2,700, 95% UL 1,300-5,000 for CT angiography). Accord-
ing to the model, 33% of projected cancers will be from scans performed at
ages of 35 to 54 years, 15% will be due to scans performed at age 18, and
66% of projected cancers will be in women.
Comment: Assuming, as the authors do, a 50% mortality rate from the
CT-induced cancers, the study suggests about 15,000 people will die as a
direct result of CT scans performed in 2007 alone. This article and that by
Smith-Berdman et al, also featured in this Abstract Section of the JVS,
together indicate that there is more radiation from CT scans and more
danger attributable to that radiation than has been previously recognized.
That this will apparently result in many thousands of excess cancers and
many thousands of excess deaths is sobering. The knee-jerk response of “just
get a CT” should be a thing of the past.
Radiation Dose Associated with Common Computed Tomography
Examinations and the Associated Lifetime Attributable Risk of Cancer
Smith-Bindman R, Lipson J, Marcus R, et al. Arch Intern Med 2009;169:
2078-86.
Conclusion: Radiation doses from diagnostic CT examinations are
higher and more variable then often quoted.
Summary: In 2007 nearly 70million CT examinations were performed
in the United States (J Am Coll Radiol 2007;4:272-84). Although a highly
important advance in medical care, CT scans deliver very high doses of
radiation compared with conventional diagnostic x-ray imaging. Increased
speed of image acquisition is also associated with higher radiation doses.
Epidemiologic data from survivors of atomic bomb explosions and patients
living near nuclear facilities during the accidental release of radioactive
materials, such as Chernobyl, has allowed calculation of long-term health
risk from radiation exposure (BEIR VII—Phase 2, National Academies
Press, Washington, DC, 2006). Surprisingly, a single CT scan can deliver an
equivalent radiation exposure to that some individuals received from the
explosion of the Hiroshima and Nagasaki atomic bombs (Health Physics
2008;95:502-7). In this study, the authors aimed to estimate the radiation
exposure associated with commonly performed CT examinations, to esti-
mate variation in radiation dose across patients and institutions and type of
CT scan, and to estimate a lifetime attributable risk of cancer associated with
these examinations.In this retrospective cross-sectional study, the authors described radia-
tion doses associated with the 11most common types of diagnostic CT scans
performed on 1119 consecutive adult patients at four San Francisco Bay area
institutions. The study took place between January 1 and May 30, 2008.
From the measured doses from the CT scans, they estimated the lifetime
cancer risk attributable to CT scans.
There were considerable differences in radiation dosage between dif-
ferent types of CT scans. Overall, the median effective dose ranged from 2
mSv for a routine head CT scan to 31 mSv for a multiphase abdominal and
pelvis CT scan. The effective dose varied widely across and within institu-
tions. There was a mean 13-fold variation between the highest and lowest
dose for each study type. The number of CT scans estimated to lead to the
development of cancer varied widely depending on the patient’s age, sex,
and type of CT examination. They estimate that cancer attributable to the
CT scan will develop in 1 in 270 women who undergo a CT coronary
angiogram at age 40 years and in 1 in 600 men. A routine head CT scan
performed at 40 years of age would produce 1 cancer in 8100 women and 1
cancer in 11,080 men. The risk approximately doubled for 20-year-old
patients and was approximately 50% lower for 60-year-old patients.
Comment:One of the most disconcerting aspects of this report is that
the actual delivered doses of radiation with CT scans were significantly
higher than commonly quoted. The median dose of a multiphase abdominal
and pelvis CT scan was nearly 400% higher than what is often quoted. There
was also a dramatic variation of effective dose between institutions and
between studies. A particular concern was the age and sex effects of varying
radiation dosage. On the basis of the highest effective dose observed in this
study, a 20-year-old woman undergoing a CT scan for suspected pulmonary
embolism where a multiphase pelvis abdomen CT scan was also used could
have an associated risk of cancer as high as 1 in 80! The study highlights
many challenges for continued used of diagnostic CT scanning. Efforts must
be made to minimize radiation exposure from CT by reducing unnecessary
studies, reducing radiation dose per study, and reducing the variations in
radiation dose across facilities and patients. (See also the abstract by Ber-
rington de Gonzalez et al in this Abstract Section of the JVS).
Screening for Abdominal Aortic Aneurysm with Electronic Clinical
Reminders
Padberg FT, Hauck K, Mercer RG, et al. Am J Surg 2009;198:670-4.
Conclusion: An electronic medical record (EMR) system can be used
to provide automatic clinical reminders for patients identified as benefitting
from abdominal aortic aneurysm (AAA) screening.
Summary: Population-based studies have determined that a single
ultrasound examination inmen aged between 65 and 75 years who have ever
smoked is cost-effective in identifying AAAs and facilitating elective repair
before rupture. There is a relative risk reduction for deaths from AAA of 43%
associated with screening protocols (Ann Intern Med 2005;142:198-202).
The rapidly increasing implementation of EMR systems raises the possibility
of having automatic reminders to remind health care providers about
patients whose profile indicates a benefit of screening for AAA.
The authors used the computerized patient record system (CPRS) of
their Veterans Affairs hospital to implement automatic electronic reminders
for AAA screening in patients who had been determined to benefit from
AAA screening. They assessed the ability of their age-prompted clinical
reminder to facilitate detection of AAA. AAA risk screening was installed in
May 2007 in their CPRS to prompt health care providers of male veterans,
ages 65-70, who had ever smoked to order a screening examination for AAA
in these patients. Screening consisted of an abbreviated ultrasound exami-
nation of the abdominal aorta using anterior-posterior and transverse plains.
The largest infrarenal aortic diameter was reported. They performed 1437
screening examinations and found 73 AAAs3 cm (5.1%), 33 AAAs4 cm
(2.3%), 15 AAAs5 cm (1.0%), and 11 AAAs greater5.5 cm (0.77%). Of
the patients found to have AAAs, 68% received counseling for abnormal
findings.
Comment: EMR systems are becoming the standard. Certainly, the
Obama Administration has made the implementation of EMR systems one
of the cornerstones of its health care reform package. This report makes it
clear such a system can facilitate appropriate screening for patients at risk for
AAA. Tomake such a systemmost effective, an order for screening should be
required for the physician to move forward in the EMR system or the
physician would have to justify why screening was not ordered for that
particular at-risk patient.
ScreeningMen for Abdominal Aortic Aneurysm: 10 YearMortality and
Cost Effectiveness Results from the Randomised Multicentre Aneu-
rysm Screening Study
Thompson SG, Gao L, Scott RAP, and theMulticentre Aneurysm Screening
Study Group. BMJ 2009;338:b2307 (doi:10.1136/bmj.b2307).Conclusion: The mortality benefit of screening men aged 65 to 74
years for abdominal aortic aneurysm (AAA) is maintained up to 10 years after
